The estimated Net Worth of Venture Partners Ix, L.P.So... is at least 3.61 百万$ dollars as of 15 November 2019. Venture So owns over 150,000 units of Nextcure Inc stock worth over 3,607,540$ and over the last 6 years Venture sold NXTC stock worth over 0$.
Venture has made over 3 trades of the Nextcure Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Venture bought 150,000 units of NXTC stock worth 5,512,500$ on 15 November 2019.
The largest trade Venture's ever made was buying 400,000 units of Nextcure Inc stock on 13 May 2019 worth over 6,000,000$. On average, Venture trades about 295,908 units every 138 days since 2018. As of 15 November 2019 Venture still owns at least 2,671,856 units of Nextcure Inc stock.
You can see the complete history of Venture So stock trades at the bottom of the page.
Venture's mailing address filed with the SEC is 3000 Sand Hill Rd, Menlo Park, CA 94025, USA.
Over the last 6 years, insiders at Nextcure Inc have traded over 0$ worth of Nextcure Inc stock and bought 1,475,000 units worth 25,387,500$ . The most active insiders traders include Advisors Llc Orbi Med Capit...、Chau Quang Khuong、Timothy M Shannon. On average, Nextcure Inc executives and independent directors trade stock every 48 days with the average trade being worth of 233,653$. The most recent stock trade was executed by Kevin N. Heller on 14 July 2020, trading 27,229 units of NXTC stock currently worth 48,195$.
nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col
Nextcure Inc executives and other stock owners filed with the SEC include: